Revenue segments as reported by the company.

Dialysis patient service revenues

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

General and administrative

Depreciation and amortization

Equity investment income (loss), net

Loss (gain) on changes in ownership interest, net

Goodwill impairment charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DaVita

DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DaVita reports robust Q4 earnings, navigates challenges with strategic focus

DaVita's Q4 2022 performance reflects financial strength and operational improvements, supported by strategic initiatives and cost discipline.
While facing challenges in operational dynamics and market uncertainties, DaVita remains focused on growth opportunities and patient-centric care.
The company's outlook for 2023 shows a commitment to long-term success through innovation, efficiency, and resilience in a changing healthcare landscape.

DaVita reports strong Q1 earnings and innovation in kidney health

DaVita's Q1 2023 earnings call highlighted strong financial performance, operational efficiency, and a focus on patient care, positioning the company well for future growth and success.
While challenges such as limited operational details and potential labor management issues exist, DaVita's strengths in cost management, innovation, and patient-centric care present opportunities for sustained performance.
Overall, DaVita's positive momentum, revised financial outlook, and commitment to enhancing healthcare services indicate a promising trajectory for the company in the competitive healthcare landscape.

DaVita reports strong Q2 earnings, navigates CMS challenges effectively

DaVita's Q2 2023 performance reflects resilience amidst challenges, with a focus on innovation and operational efficiencies.
The company faces industry headwinds but remains committed to driving growth and enhancing patient care.
Analysts' questions highlighted key concerns and opportunities, showcasing DaVita's proactive approach to addressing industry dynamics.
Overall, DaVita's strategic focus on performance and stakeholder communication positions the company for continued success.

DaVita reports robust Q3 performance and eyes growth opportunities

DaVita's Q3 2023 Earnings Call highlighted strong financial results, operational priorities, and growth prospects. Despite challenges in managing drug impacts and market perception, the company remains focused on delivering quality care and driving shareholder value. Opportunities in CKD progression, shareholder returns, and IKC business improvement position DaVita for future success.

DaVita surpasses 2023 guidance, eyes growth and efficiency in 2024

DaVita's Q4 2023 Earnings Call showcased strong financial performance, exceeding guidance and highlighting a focus on efficiency and cost savings.
While facing challenges like legal proceedings and capacity utilization, DaVita remains optimistic about financial recovery and growth opportunities in 2024.
The company's successful Integrated Kidney Care program and commitment to driving operating performance position it well for continued success in the healthcare market.

DaVita reports robust Q1 earnings, eyes international expansion opportunities

DaVita's Q1 2024 performance reflects strong financial results and a strategic focus on kidney care solutions and international growth.
While challenges like the Change Healthcare outage were addressed, opportunities in expanding markets and enhancing patient care services are evident.
Management's commitment to quality care and sustainable growth positions DaVita well for continued success in the healthcare sector.

DaVita reports robust Q2 earnings, supports CMS proposal for growth

DaVita's Q2 2024 earnings call highlighted strong financial performance and strategic initiatives to drive growth.
While facing challenges in certain operational areas, the company's proactive stance on policy advocacy and financial guidance raise optimism.
Opportunities lie in optimizing operational metrics, managing costs effectively, and engaging stakeholders for sustained growth.

DaVita maintains financial course amidst challenges, eyes growth opportunities

DaVita's Q3 performance met expectations despite supply chain disruptions, with full-year guidance reaffirmed.
The company faces short-term challenges from hurricane impacts and regulatory uncertainties.
Opportunities lie in market changes and growth initiatives, though long-term guidance remains pending.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IAMGOLD

Norwegian Cruise Line

Sylvamo Corp

Tenet Healthcare

Investors target stocks that have been on a bullish run lately. Stocks like THC, SLVM, DVA, NCLH and IAG are seeing price strength, and the momentum is likely to continue.

5 Stocks Trading Near 52-Week High With Room to Rise Further

DaVita HealthCare (DVA) closed the most recent trading day at $163.08, moving +0.51% from the previous trading session.

DaVita HealthCare (DVA) Advances While Market Declines: Some Information for Investors

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy DaVita (DVA) Stock?

Here is how DaVita HealthCare (DVA) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year.

Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year?

DVA stock has the potential to continue its uptrend on the back of better revenues per treatment as well as growth of the overall dialysis market.

DaVita Stock Rallies 17% in 3 Months: Is it Still Worth Buying?

Does DaVita HealthCare (DVA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why DaVita HealthCare (DVA) is a Great Choice

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why DaVita HealthCare (DVA) is a Top Momentum Stock for the Long-Term

Moody's

Occidental Petroleum

In August, Warren Buffett's Berkshire Hathaway (NYSE: BRK-B) became the first non-tech U.S.

3 Stocks Warren Buffett Owns More Than 10% of Right Now

DaVita HealthCare (DVA) closed the most recent trading day at $163.16, moving -0.65% from the previous trading session.

Here's Why DaVita HealthCare (DVA) Fell More Than Broader Market

In the most recent trading session, DaVita HealthCare (DVA) closed at $164.22, indicating a -0.59% shift from the previous trading day.

DaVita HealthCare (DVA) Stock Falls Amid Market Uptick: What Investors Need to Know

Kidney care leader provides free health screenings and resources to create awareness around kidney disease and open discussion around health care access DENVER , Sept. 17, 2024 /PRNewswire/ -- DaVita (NYSE: DVA), a leading provider of kidney care services, today announced the launch of its 2024 nationwide community health tour beginning September 24.

DaVita Accelerates Commitment to Community Health with Nationwide Tour

Boot Barn Hlds

Limbach Holdings

Royal Caribbean Cruises

Ubiquiti Inc

LMB, UI, RCL, DVA and BOOT are five stocks with explosive relative price strength.

5 Stocks to Benefit From Relative Price Strength Trends

Intuitive Surgical

SharkNinja Inc

Stocks making new highs tend to make even higher highs, particularly when positive earnings estimate revisions hit the tape. And that's precisely what these three companies have seen.

3 Red Hot Stocks Flashing Buy Signals: DVA, ISRG, SN

DaVita HealthCare (DVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

DaVita Inc. (DVA) Soars to 52-Week High, Time to Cash Out?

DENVER , Sept. 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that David Maughan will assume the role of chief operating officer.

DaVita Appoints David Maughan New Chief Operating Officer, Mike Staffieri Steps into Emeritus Role

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why DaVita HealthCare (DVA) is a Strong Value Stock

Freshpet

Netflix

Tyler Technologies

W. R. Berkley

Buying a stock is easy, but buying the right stock without a good strategy is incredibly hard. Here are the five top-performing stocks to buy now or put on a watchlist.

These Are The Five Best Stocks To Buy And Put On A Watchlist Now

DaVita HealthCare (DVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

DaVita HealthCare (DVA) Upgraded to Strong Buy: Here's What You Should Know

Charter Communications

Warren Buffett has obliterated the market's returns since becoming CEO of Berkshire Hathaway (NYSE:BRK-A)(NYSE:BRK-B) in the mid-1960s.

These Are the 2 Cheapest Stocks Warren Buffett Owns. Are They a Top Buy in September?

DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock?

DaVita HealthCare (DVA) Up 13% Since Last Earnings Report: Can It Continue?

DVA's shares gain on the back of strong fundamentals. However, dependence on commercial payers can be a cause of concern.

DaVita Rallies 44% Year to Date: What's Driving the Stock?

DaVita HealthCare (DVA) is a Great Momentum Stock: Should You Buy?

Assurant

RCM Technologies

RCMT, AIZ and DVA made it to the Zacks Rank #1 (Strong Buy) value stocks list on August 30, 2024.

Best Value Stocks to Buy for August 30th

Duke Energy

Johnson & Johnson

If you are a Johnson & Johnson investor and have been enjoying the stock's steady dividends, it may be time to look elsewhere. As of this moment, we find DaVita - a healthcare company focused on kidney dialysis services - and Duke Energy - an electric and natural gas utility company based in North Carolina - as more attractive buys than Johnson & Johnson.

Drop Johnson & Johnson, Pick These Steady Eddie Stocks?

Philip Morris

Starwood Property

Broad markets, although continuing to trend higher, are showing signs of increasing volatility and uncertainty. While there has been a strong rally in stocks since the sharp correction earlier in the month, there is something peculiar happening under the surface.

News for DaVita Stock (DVA)